Urška Janžič (Author), Urška Bidovec (Author), Katja Mohorčič (Author), Loredana Mrak (Author), Nina Fokter Dovnik (Author), Marija Ivanović (Author), Maja Ravnik (Author), Marina Čakš (Author), Erik Škof (Author), Jerneja Debeljak (Author), Peter Korošec (Author), Matija Rijavec (Author)

Abstract

Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.

Keywords

onkološko zdravljenje;imunogenost;osnovno cepljenje mRNA;čvrsti tumorji;anticancer treatment;immunogenicity;mRNA-based vaccination;solid cancer;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Publisher: Future Medicine
UDC: 616-006
COBISS: 111378179 Link will open in a new window
ISSN: 1479-6694
Views: 141
Downloads: 45
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Source comment: Soavtorji: Urška Bidovec-Stojković, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čaks, Erik Škof, Jerneja Debeljak, Peter Korošec & Matija Rijavec;
Pages: str. [1-10]
Volume: ǂVol. ǂ
Issue: ǂiss. ǂ
Chronology: 2022
DOI: 10.2217/fon-2022-0148
ID: 15730080